US FDA Continues Cannabinoid Analysis Required In FY2021 Budget

FDA is testing cannabidiol and other cannabinoids for whether labeled amounts match what’s in a product, says CFSAN Deputy Director Doug Stearn. The work is supported with $5m provided in the agency’s FY21 appropriation.

The US Food and Drug Administration continues testing, which Congress funded in its current budget, to find disparities between labeled cannabinoid levels and the amounts in products as momentum builds on Capitol Hill behind legislation that would direct the agency to make lawful the ingredients’ use in dietary supplements.

Doug Stearn, regulatory affairs deputy director at the FDA’s Center for Food Safety and Applied Nutrition, says while the agency’s...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cannabis/CBD

French Agency Proposes Effective EU Ban On CBD In Foods And Cosmetics

 
• By 

France's food safety regulator ANSES is proposing a reproductive toxicity category 1B classification for CBD under the EU's CLP regulation, which would mean an effective ban on CBD in cosmetics and foods. However, French hemp industry association UIVEC hopes that new evidence coming out of a European Commission review will put the issue to bed before it gets that far.

Senate Hemp Regulation Bill’s Broad Prohibition On Synthetics In Supplements Has Industry Attention

 

Provision in Wyden and Merkley’s “Cannabinoid Safety and Regulation Act” referencing FDA authority outside hemp-derived ingredients could provide agency with needed authority to force from the market products labeled as supplements but containing drugs or eliminate the use of many safe ingredients in supplements.

Senate Hemp Regulation Bill Offers Option To House’s Blanket Limit On Levels Of All THCs

 

Democrats Wyden and Merkley author Cannabinoid Safety and Regulation Act to limit sales to consumers 21 and older and authorize FDA to order recalls and impose bans on cannabis products with dangerous chemicals or additives. It also would establish regulatory structure for using cannabinoids found naturally in hemp and allowing “semi-synthetic” ingredients while prohibiting artificial or fully synthetic cannabinoids.

Tobacco Giant Philip Morris Sells Medical Device Business, Keeps Consumer Health Footprint

 
• By 

Philip Morris described a scenario of being essentially blacklisted by the health care sector and its CDMO partners as it threw in the towel on its £1.1bn acquisition of UK inhalation specialist Vectura. It agreed to offload the firm at a fraction of the initial cost.

More from Ingredients & Safety

House OMUFA Reauthorization Bill Takes On Clarifying Standards For Tests To Meet GRASE

 

Health Subcommittee will discuss reauthorizing OMUFA during a hearing on how to “maintain and improve” the public health workforce and rural health as well as access to OTC medicines.

Pharma Deutschland Seeks To Enter Urban Wastewater Legal Dispute

 
• By 

The Urban Wastewater Treatment Directive “in its current form, is at an end,” insists Pharma Deutschland CEO Jörg Wieczorek. To put the directive to bed once and for all, the association has applied for leave to intervene in the ongoing EU legal battle in its own right.

UK FSA Issues New Guidelines For CBD And THC Max Levels

 
• By 

Based on advice from its advisory committees, the UK's Food Standards Agency is encouraging businesses to meet an acceptable daily intake of 10mg CBD per day and a safe upper limit of 0.07mg THC per day.